Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

You may be eligible if

• Histologically or cytologically confirmed surgically incurable solid tumor orhematologic malignancy for which no standard or palliative therapy exists oris no longer effective
• * All tumor types are eligible, including:
• * Chronic myelogenous leukemia or other Philadelphia chromosome-positive leukemia OR
• * Gastrointestinal stromal tumors
• Patients with gliomas that require corticosteroids or anticonvulsants must beon a stable dose and seizure-free for 1 month
• No unstable or untreated (non-irradiated) brain metastases
• Performance status - ECOG 0-2
• Performance status - Karnofsky 60-100%
• More than 3 months
• WBC at least 3,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• No active hemolysis
• See Surgery
• No evidence of biliary sepsis
• Creatinine normal
• Creatinine clearance at least 60 mL/min
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Able to swallow pills
• No other uncontrolled concurrent illness that would preclude study participation
• No ongoing or active infection
• No uncontrolled diarrhea
• No psychiatric illness or social situation that would preclude study compliance
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception during and for 6 months after study completion
• At least 24 hours since prior colony-stimulating factors
• No concurrent colony-stimulating factors
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• See Disease Characteristics
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy and recovered
• See Disease Characteristics
• At least 10 days since prior placement of shunt for treatment of biliary obstruction
• At least 14 days since prior major surgery
• No prior solid organ transplantation
• No other concurrent investigational agents
• No concurrent therapeutic doses of warfarin for anticoagulation
• No other concurrent investigational or commercial agents or therapies for treatment of this disease
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No concurrent acetaminophen of more than 4,000 mg/day